Efficacy, tolerability, and safety of transition from beraprost to selexipag in patients with pulmonary arterial hypertension.

Efficacy, tolerability, and safety of transition from beraprost to selexipag in patients with pulmonary arterial hypertension. - Efficacy, tolerability, and safety of transition from beraprost to selexipag

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000025176

Enrollment

Registered

2016-12-15

Start date

2017-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary arterial hypertension

Interventions

Medicine transition from beraprost to selexipag In accordance with the Japanese package insert (http://www.info.pmda.go.jp/go/pack/2190037F1020_1_02/), selexipag is initiated at a dose of 0.2mg t

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with pulmonary arterial hypertension who had received beraprost for > 3 months. 2. Patients with pulmonary arterial hypertension who have a pulmonary vascular resistance of at least 5 Wood units (400 dyn?sec?cm-5) 3. Patients with pulmonary arterial hypertension who give a written informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients who added newly concomitant drugs within last 3 months 2. Patients who is expected to intolerable selexipag 3. Patients who had clinically unstable right heart failure within the last 3 months

Design outcomes

Primary

Measure	Time frame
Pulmonary arterial resistance (PVR) at week 24 from baseline	—

Secondary

Measure	Time frame
Other variables at week 24 from baseline (1) Right heart catheterization (PCWP, PAP, RVP, CO/CI) (2) NT-proBNP (3) WHO functional class	—

Countries

Japan

Contacts

Public ContactKeiichi ODAGIRI

Hamamatsu University School of Medicine Center for Clinical Research/ Department of Clinical Pharmacology and Therapeutics

kodagiri@hama-med.ac.jp053-435-2850

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026